Pegaspargase 3750 Units/5 ml

Therapeutic Indication:

Oncaspar is indicated as a component of antineoplastic combination therapy in Acute Lymphoblastic Leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.

  • Composition: Pegaspargase 3750 Units/5 ml.
  • Pharmaceutical Form: Powder for Solution for Injection or Infusion.
  • Method of Administration: Intravenous or intramuscular.
  • How Supplied: Single 5 ml vial.
  • Manufacturer: Les Laboratoires Servier, France.

Contact Us

Contact us today to find out more about our services and discuss your enquiries.